Business
Cellectis Presents Epigenetic Editing Platform to Turn Genes Off Without Altering DNA at the ASGCT Annual Meeting
NEW YORK, April 27, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, today presents new research on a TALE-based epigenetic editing approach, that does not cut or permanently modify the DNA sequence, making it a potentially safer alternative for genome editing, at the American Society of Gene and Cell Therapy (ASGCT) annual m
About this update from Cellectis S.a.
[{"type":"image","alt":"Cellectis Inc.","displaySize":"","headline":null,"caption":"Cellectis Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":119,"url":"https://media.zenfs.com/en/globenewswire.com/f68f579f9ddafa91af53fffe1d842d97"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/vWIHOIMRZXxX7Vcj5Kxj2w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE2Nw--/https://media.zenfs.com/en/globenewswire.com/f68f579f9ddafa91af53fffe1d842d97","width":300,"height":119}},"lazy":false},{"type":"text","content":"NEW YORK, April 27, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, today presents new research on a TALE-based epigenetic editing approach, that does not cut or permanently modify the DNA sequence, making it a potentially safer alternative for genome editing, at the American Society of Gene and Cell Therapy (ASGCT) annual meeting, that will be held on May 11-15, in Boston (MA).","length":555,"tagName":"p"},{"type":"text","content":"The data will be presented in a poster: ","length":39,"tagName":"p"},{"type":"text","content":"Title: TALE-based epigenetic modulators show sustained knock-down of target genes in T-cells and HEPG2 via a high-throughput multiplex screening platform","length":153,"tagName":"p"},{"type":"text","content":"Transcription activator-like effector-based epigenetic modulators (TALEM) are engineered fusion proteins consisting of a TALE DNA-binding domain with functional domains that mediate epigenetic modifications. These proteins can be precisely guided to a target location in the genome to switch genes on or off through a process known as epigenetic editing.","length":354,"tagName":"p"},{"type":"text","content":"Unlike traditional gene editing tools, this approach does not induce DNA breaks and DNA sequence modifications, making it a potentially safer alternative for genome editing.","length":173,"tagName":"p"},{"type":"text","content":"In this work, Cellectis developed a high-throughput screening system capable of rapidly assembling and testing hundreds of these TALEM, identifying which combinations are most effective at regulating a given gene.","length":213,"tagName":"p"},{"type":"text","content":"The results: ","length":12,"ta...